Industry’s Clinical Pipeline Shows High Level Of Innovation, Report Says
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
A new study by the Analysis Group, with funding from PhRMA, shows nearly 8,000 new molecule/indication-specific “projects” in clinical development, and approximately 70% are potential first-in-class treatments.